CORRECTION: NeoGenomics Ticker Is NEO
$NE
$NEO
Oil & Gas Production
Energy
Precision Instruments
Health Care
CORRECTION: NeoGenomics Ticker Is NEO
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 12/10/2025 | $33.00 | Overweight → Neutral | Analyst | |
| 9/2/2025 | Buy → Neutral | Clarksons Platou | ||
| 7/30/2025 | Buy → Neutral | BTIG Research | ||
| 7/29/2025 | Outperform → Mkt Perform | William Blair | ||
| 7/10/2025 | $32.00 | Buy → Neutral | Citigroup | |
| 5/28/2025 | $30.00 | Neutral → Overweight | Analyst | |
| 5/15/2025 | Neutral | Guggenheim | ||
| 4/30/2025 | $9.00 | Outperform → Market Perform | Leerink Partners |
HOUSTON, Feb. 2, 2026 /PRNewswire/ -- Noble Corporation plc ("Noble" or the "Company") (NYSE:NE) today announces plans to report financial results for the fourth quarter and full year 2025 on Wednesday, February 11, 2026 after the U.S. market close. The Company's earnings press release and accompanying earnings presentation will be available on the Noble website at www.noblecorp.com. Noble will host a conference call related to its fourth quarter and full year 2025 results on Thursday, February 12, 2026 at 8:00 a.m. U.S. Central Time. Interested parties may dial (800) 715-9871 and refer to conference ID 31391 approximately 15 minutes prior to the scheduled start time. Alternatively, partic
HOUSTON, Jan. 28, 2026 /PRNewswire/ -- Noble Corporation plc (NYSE:NE, ", Noble", , or the ", Company", )) today announced that it has completed the sale of five jackup rigs to Borr Drilling Limited (NYSE:BORR, ", Borr", )) for $360 million. The Company generated approximately $210 million in cash plus $150 million in seller notes from the sale of the Noble Tom Prosser, Noble Mick O'Brien, Noble Regina Allen, Noble Resilient and Noble Resolute. Noble intends to operate two rigs – Noble Mick O'Brien and Noble Resolute – under a bareboat charter agreement with Borr until December 2026, as well as the Noble Resilient through the remainder of its current contract term (including exercise of any
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Tuesday, February 17, 2026. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 5
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - Noble Corp plc (0001895262) (Issuer)
4 - Noble Corp plc (0001895262) (Issuer)
4 - Noble Corp plc (0001895262) (Issuer)
SCHEDULE 13G/A - Noble Corp plc (0001895262) (Subject)
8-K - NEOGENOMICS INC (0001077183) (Filer)
8-K - NEOGENOMICS INC (0001077183) (Filer)
Analyst downgraded Noble Corporation from Overweight to Neutral and set a new price target of $33.00
Clarksons Platou downgraded Noble Corporation from Buy to Neutral
BTIG Research downgraded NeoGenomics from Buy to Neutral
– Anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million; full-year 2025 revenue of $727 million – – Announces Chief Financial Officer transition – NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company's Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue For the fourth quarter of 2025, NeoGenomics expects to report total revenue of approximately $190 million, representing year-over-year growth of 11%. For the full-year 2025, Neo
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran John P. "Jack" Kenny to its Board of Directors. Mr. Kenny is filling the seat vacated by Alison Hannah, MD, who is rotating off the Board after more than ten years of dedicated service. Mr. Kenny brings to the NeoGenomics Board over three decades of diverse executive, commercial, and operational experience and a track record of success in the diagnostics and lab services businesses. He most recently served as President, Chief Executive Officer and Board Director of Meridian Bioscience, a fully i
NEW YORK, Sept. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 22, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Uber Technologies Inc. (NYSE:UBER) will replace Charter Communications Inc. (NASD: CHTR) in the S&P 100. Charter Communications will remain in the S&P 500.AppLovin Corp. (NASD: APP), Robinhood Markets Inc. (NASD: H
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
SC 13D/A - Noble Corp plc (0001895262) (Subject)
SC 13D/A - Noble Corp plc (0001895262) (Subject)
HOUSTON, Feb. 2, 2026 /PRNewswire/ -- Noble Corporation plc ("Noble" or the "Company") (NYSE:NE) today announces plans to report financial results for the fourth quarter and full year 2025 on Wednesday, February 11, 2026 after the U.S. market close. The Company's earnings press release and accompanying earnings presentation will be available on the Noble website at www.noblecorp.com. Noble will host a conference call related to its fourth quarter and full year 2025 results on Thursday, February 12, 2026 at 8:00 a.m. U.S. Central Time. Interested parties may dial (800) 715-9871 and refer to conference ID 31391 approximately 15 minutes prior to the scheduled start time. Alternatively, partic
HOUSTON, Jan. 28, 2026 /PRNewswire/ -- Noble Corporation plc (NYSE:NE, ", Noble", , or the ", Company", )) today announced that it has completed the sale of five jackup rigs to Borr Drilling Limited (NYSE:BORR, ", Borr", )) for $360 million. The Company generated approximately $210 million in cash plus $150 million in seller notes from the sale of the Noble Tom Prosser, Noble Mick O'Brien, Noble Regina Allen, Noble Resilient and Noble Resolute. Noble intends to operate two rigs – Noble Mick O'Brien and Noble Resolute – under a bareboat charter agreement with Borr until December 2026, as well as the Noble Resilient through the remainder of its current contract term (including exercise of any
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Tuesday, February 17, 2026. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 5
